Decreased Proteolytic Activity of the Mitochondrial Amyloid-β Degrading Enzyme, PreP Peptidasome, in Alzheimer's Disease Brain Mitochondria by Alikhani, Nyosha et al.




Decreased Proteolytic Activity of the
Mitochondrial Amyloid- Degrading
Enzyme, PreP Peptidasome, in Alzheimer’s
Disease Brain Mitochondria
Nyosha Alikhania,e,1, Lan Guoa,1, Shiqiang Yana, Heng Dua, Catarina Moreira Pinhoe, John Xi Chenf ,
Elzbieta Glasere and Shirley ShiDu Yana,b,c,d,∗
aDepartment of Surgery
bDepartment of Pathology and Cell Biology, College of Physicians and Surgeons of Columbia University,
New York, NY, USA
cDepartment of Taub Institute for Research on Alzheimer’s disease and the Aging Brain,
College of Physicians and Surgeons of Columbia University, New York, NY, USA
dDepartment of Pharmacology and Toxicoogy and Higuchi Bioscience Center, School of Pharmacy,
University of Kansas, Lawrence, KS, USA
eDepartment of Biochemistry and Biophysics, Stockholm University, Stockholm, Sweden
f Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
Accepted 20 May 2011
Abstract. Accumulation of amyloid- peptide (A), the neurotoxic peptide implicated in the pathogenesis of Alzheimer’s
disease (AD), has been shown in brain mitochondria of AD patients and of AD transgenic mouse models. The presence of
A in mitochondria leads to free radical generation and neuronal stress. Recently, we identified the presequence protease,
PreP, localized in the mitochondrial matrix in mammalian mitochondria as the novel mitochondrial A-degrading enzyme. In
the present study, we examined PreP activity in the mitochondrial matrix of the human brain’s temporal lobe, an area of the
brain highly susceptible to A accumulation and reactive oxygen species (ROS) production. We found significantly lower hPreP
activity in AD brains compared with non-AD age-matched controls. By contrast, in the cerebellum, a brain region typically spared
from A accumulation, there was no significant difference in hPreP activity when comparing AD samples to non-AD controls.
We also found significantly reduced PreP activity in the mitochondrial matrix of AD transgenic mouse brains (Tg mAPP and
Tg mAPP/ABAD) when compared to non-transgenic aged-matched mice. Furthermore, mitochondrial fractions isolated from
AD brains and Tg mAPP mice had higher levels of 4-hydroxynonenal, an oxidative product, as compared with those from
non-AD and nonTg mice. Accordingly, activity of cytochrome c oxidase was significantly reduced in the AD mitochondria.
These findings suggest that decreased PreP proteolytic activity, possibly due to enhanced ROS production, contributes to A
accumulation in mitochondria leading to the mitochondrial toxicity and neuronal death that is exacerbated in AD. Clearance of
mitochondrial A by PreP may thus be of importance in the pathology of AD.
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INTRODUCTION
Accumulation of amyloid- peptide (A) is a hall-
mark of Alzheimer’s disease (AD) according to the
amyloid cascade hypothesis, and is produced by reg-
ulated intramembrane proteolysis of the amyloid-
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protein precursor (APP) via sequential cleavage by
- and -secretases [1, 2]. Extracellular accumulation
of A in the form of senile plaques has been detected
in individuals with AD [3, 4]. It is also known that
there is a reduction of mitochondrial volume during
early stage AD, and this fact has led to an increased
focus on intracellular events, especially the role of
mitochondria, in AD [5–7]. A peptides have been
found in mitochondria of the AD brains as well as in
AD transgenic mice overexpressing A [8–14]. Accu-
mulation of mitochondrial A has been shown at a
young age in AD transgenic mice, before extracellu-
lar plaques are formed [8, 9]. Notably, mitochondrial
A accumulation significantly correlates to the abnor-
mal mitochondrial function as shown by impaired
mitochondrial respiratory function, inactivated mito-
chondrial respiratory key enzyme, and reduced ATP
levels [8–13, 15–17].
APP binds to mitochondria and is incompletely
translocated leaving the A region outside the mito-
chondrial membrane [18–20], suggesting that A
cannot be produced inside the mitochondria. We have
recently shown in vitro that A is transported into
mitochondria via the protein Translocase of the Outer
Membrane (TOM) machinery [14]. The cell surface
RAGE receptor (receptor for advanced glycation end
product) also contributes to transport of A from the
cell surface to the intracellular space including mito-
chondrial localization. RAGE-deficient neurons dis-
played a decrease in uptake of A and protection from
A-induced mitochondrial dysfunction [21]. Further,
A-targeted mitochondrial proteins, ABAD (A-
binding alcohol dehydrogenase) and cyclophilin D,
are upregulated in neurons of AD patients and AD
transgenic mice [10, 12,13, 15, 22, 23]. Interaction of
A with ABAD in AD mitochondria leads to elevated
reactive oxygen species (ROS) in neurons and neu-
ronal death [10, 24–26]. The abrogation of cyclophilin
D in A-rich mitochondria attenuates mitochondrial
ROS accumulation/production and protects against
aberrant mitochondrial and neuronal function.
A few years ago, we identified a novel mitochon-
drial peptidasome, the presequence protease (PreP),
that is responsible for A degradation in mitochon-
dria [27, 28]. PreP is a metallopeptidase, localized
in the mitochondrial matrix in mammals, contain-
ing an inverted zinc-binding motif. It belongs to the
pitrilysin oligopeptidase family (M16 C), which also
includes insulin degrading enzyme (IDE), implicated
in AD [29–31]. PreP was originally identified as a
protease degrading mitochondrial presequences [32],
but has also been shown to degrade other unstruc-
tured peptides up to 70 amino acid residues in length
[33, 34], including A. We have characterized the
human PreP homologue (hPreP) in brain mitochon-
dria and shown its capacity to degrade the A peptides
including A1-40, A1-42, and Arctic A. Immuno-
inactivation studies in human brain mitochondria using
hPreP antibodies showed complete inhibition of prote-
olytic activity against A, demonstrating that hPreP is
the protease responsible for degradation of this toxic
peptide [27]. However, it has not yet been proven
whether PreP activity is relevant to amyloid pathol-
ogy and mitochondrial A accumulation and whether
its activity is altered in an A-rich environment, such
as in the AD brain and AD mouse models.
Molecular homology modeling of hPreP based on
the crystal structure of Arabidopsis thaliana PreP,
AtPreP, refined at 2.1 Å [35], revealed four topologi-
cally similar domains creating two halves, connected
by a hinge region. These two halves enclose a large
chamber wherein the proteolytic activity occurs. This
molecular modeling was followed by the identification
of Cys90 in the first domain and Cys527 at the hinge
region that together form a disulfide bridge (under oxi-
dizing conditions) resulting in a complete inhibition of
the enzyme.
In the present study, we investigated the alterations
of hPreP activity in AD individuals and transgenic AD
mouse models. We studied hPreP activity in human
brain (temporal lobe) mitochondrial matrix from AD
individuals and in non-AD age-matched controls. We
also investigated hPreP activity in the AD spared
region, the cerebellum, which is usually free from
A accumulation. In an AD transgenic mouse model,
we compared PreP activity overexpressing mAPP/
A and mAPP/ABAD at different ages to aged-
matched non-transgenic littermates. The selected AD
mouse models were well-suited to our strategy for
determining whether enhancing/accelerating A accu-
mulation and oxidative stress in mitochondria alter
PreP expression/activity since these animals have been
characterized with respect to mitochondrial A accu-
mulation, mitochondrial and neuronal function, and
neuropathological and behavioral endpoints [8–10, 12,
13, 26, 51].
MATERIALS AND METHODS
Human brain samples and transgenic (Tg) mice
Human brain tissues of temporal lobe and cere-
bellum from individuals with AD and age-matched
non-AD controls were obtained from the New York
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Brain Bank at Columbia University (Table 1). The fol-
lowing Tg mice were used in these studies: Tg mAPP
overexpressing human mutant form of amyloid-
protein precursor (mAPP, J-20 line) and A, Tg
ABAD mice overexpressing neuronal ABAD driven
by PDGF-B chain promoter, Tg mAPP/ABAD mice
overexpressing both mutant human form of APP and
ABAD, and non-transgenic littermate controls (nonTg)
[8–10, 12, 13, 37, 51]. Animal studies were approved
by the Animal Care and Use Committee of Columbia
University in accordance with the National Institute of
Health guidelines for animal care.
Isolation of mitochondria
Human and mice brain mitochondria were iso-
lated using Percoll gradient as described previously
[8, 12]. Briefly, human temporal lobe, human cere-
bellum and cerebral lobe from mice brain were
minced with scissors and washed two times with isola-
tion buffer (225 mM mannitol, 75 mM sucrose, 1 mM
EGTA, 5 mM HEPES, and 1 mg/ml bovine serum albu-
min [BSA], pH 7.2) to remove contaminating blood,
followed by homogenization in a glass Teflon homog-
enizer in 14 ml isolation buffer. Homogenates were
then centrifuged at 1500 g for 5 min. Supernatant was
applied to 14% Percoll and centrifuged at 12,000 g for
10 min. The mitochondrial pellets were re-suspended
and centrifuged at 8000 g for 10 min followed by a
washing and re-suspension in 100 l sonication buffer
(20 mM HEPES-KOH, 10 mM MgCl2, pH 7.5). Pro-
tein concentration was determined by Bio-Rad protein
concentration kit with BSA as standard.
Preparation of brain mitochondria matrix
Isolated brain mitochondria were diluted with a
sonication buffer to a final concentration of 8 g/l
and incubated 30 min at 4◦C followed by sonication
4×30 s. To obtain the matrix fraction, samples were
then centrifuged at 70,000 rpm for 1 h and the super-
natant containing the matrix proteins was used in the
PreP degradation assay studies.
PreP expression levels
20 g of the isolated human and mice brain mito-
chondrial matrix were subjected to a 12% Bis-Tris
gel (Invitrogen, CA), run in 1 × MES buffer, and
transferred to nitrocellulose membrane HybondTM
(Amersham Biosceinece) for 1 h at 100 V. The mem-
brane was blocked overnight in 5% milk-PBS. For
detection of PreP, antibodies against hPreP were
applied at a dilution of [1:1500–2000] for 1 h followed
by detection with horseradish peroxidase-conjugated
anti-rabbit secondary antibody (1:2500) and ECL (GE
Healthcare). Hsp60 expression levels were detected by
antibody raised against Hsp60, 1:2000 for 1 h followed
by detection with horseradish peroxidase-conjugated
anti-mouse secondary antibody (1:2500) and ECL (GE
Healthcare).
Degradation assays
The degradation assay for studying proteolytic activ-
ity of hPreP in human brain mitochondrial matrix
fractions was conducted by using 20 g isolated matrix
protein and the following substrates: 0.25 g pF1,
a mitochondrial presequence derived from the F1-
subunit of the Nicotiana plumbaginifolia ATP synthase
N5.7 pF1(2–54) [36], 0.25 g Biotin-labeled A1-40
and 0.25 g Biotin-labeled A1-42 in a degradation
buffer containing 20 mM HEPES-KOH pH 8.0, and
10 mM MgCl2. For inhibitory studies, 20 mM ortho-
phenathroline (oPh) was pre-incubated with 20 g
of brain mitochondrial matrix protein on ice for
10 min before the addition of substrate. For studies of
PreP activity under oxidized conditions, 20 g matrix
protein was pre-incubated with 0.1 mM and 1 mM
K3Fe(CN)6 for 10 min on ice before addition of 1 g
A1-40. The immuno-inactivation was performed by
pre-incubating mitochondrial fractions with 6 g of
antibodies raised against hPreP or 18 g of antibod-
ies raised against the presequence of F1 subunit of
the ATP synthase from N. plumbaginifolia, pF1 at
4◦C for 30 min before the addition of Biotin-labeled
A1-40. Samples were incubated for 2.5 h at 37◦C.
Reactions were stopped by the addition of 2× sam-
ple buffer, analyzed on NuPAGE 12% Bis-Tris gel
(Invitrogen, CA), and run in 1×MES buffer. Proteins
were electrophoretically transferred to nitrocellulose
membrane HybondTM (Amersham Bioscience) for 1 h
at 100 V. For pF1 identification, the nitrocellulose
membrane was blocked overnight in 5% milk-PBS
followed by incubation with pF1 antibody (1:2000)
and detection with horseradish peroxidase-conjugated
anti-rabbit secondary antibody (1:2500) and ECL (GE
Healthcare). For analyzing the degradation of Biotin
labeled A1-40 and Biotin labeled A1-42 (Biotin-
LC- A1-40, Biotin-LC- A1-42), the nitrocellulose
membrane was dried overnight at 25◦C followed by
blocking with 2% milk-PBS for 1 h. Immunoblotting
was performed with ExtraAvidin Peroxidase Conju-
gate 1:3000 (Sigma) and detection with ECL.
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Measurement of HNE in brain mitochondrial
fractions
Brain mitochondria isolated from human subjects
and Tg mice were sonicated in the cold isolation buffer,
then centrifuged at 10,000 g for 10 minutes at 4◦C. Lev-
els of 4-hydroxynonenal (HNE) were measured using
commercial ELISA Kit (Cell Biolabs, Inc.).
Measurement of cytochrome c oxidase activity
Cytochrome c oxidase activity in the cortical mito-
chondria from AD and non-AD temporal pole and
cerebellum was measured as previously described
[12, 13].
Statistical analysis
Quantification analysis was performed by using
NIH Image J software. Statistical analyses were
performed using STATVIEW software. One-way
ANOVA was used for repeated measures followed
by Fisher’s Protected Least Significant Difference
for post-hoc comparisons. Results are expressed as
mean ± Standard Error Mean (SEM). p < 0.05 was
considered significant.
RESULTS
Decreased PreP proteolytic activity in AD brain
mitochondria
It is well established that the temporal lobe is one of
the most highly susceptible regions to the A accumu-
lation in the AD brain, whereas A accumulation and
aggregation are usually not found in the cerebellum.
Therefore, we investigated hPreP activity in AD brain
mitochondrial matrix fractions from these two areas of
the brain and compared such activity to age-matched
non-AD individuals. Measurement of PreP proteolytic
activity in AD and mAPP brain mitochondria was
based on the capacity of PreP in the mitochondrial
matrix for degrading exogenous biotin-labeled A
(A40 or A42) or non-A peptide (F1 presequence,
pF1). The amount of A or pF1 peptides degraded
by PreP from AD brains or APP mice compared to
those from non-AD or nonTg mice was representative
of changes in PreP activity. We isolated brain mito-
chondrial matrix proteins from the temporal lobes and
cerebella of 12 AD patients and 8 control patients
(Table 1). The isolated human brain mitochondrial
fraction showed proteolytic activity against biotin-
labeled A1-40, A1-42, and pF1 (Fig. 1A-C). There
was a significant reduction in proteolytic activity of
hPreP in the mitochondrial matrix extracted from tem-
poral lobes of AD patients compared with age-matched
non-AD individuals for all three substrates [biotin-
labeled A1-40 (p = 0.0156), biotin-labeled A1-42
(p = 0.02), and pF1 (p = 0.0136)] (Fig. 1A-C).
To determine the effect of PreP proteolytic activity,
ortho-phenantroline (oPh), a metalloprotease inhibitor,
was used for the inhibition study in the degradation
assay. The degradation activity of PreP was completely
abolished in the presence of oPh (Fig. 1D). The strong
immunoreactive biotin A or pF1 bands were notice-
able due to the loss of PreP proteolytic activity in the
presence of oPh inhibitor (Fig. 1D, lanes 3 and 7 for
degrading A and Fig. 2D, lane 3 for degrading pF1),
as compared to those without oPh treatment (Figs. 1D
and 2D, lane 2).
To determine the PreP-dependent degradation of
A, we performed the following two experiments as
shown in Fig. 1D: 1) immuno-inactivation assay with
a specific antibody against PreP; and, 2) immuno-
inactivation assay with unrelated control antibody,
such as a specific antibody to the F1 presequence,
which is a non-A substrate for PreP. In the absence
of PreP antibody, mitochondrial matrix PreP com-
pletely degraded biotin-labeled A (Fig. 1D, lanes 2
and 6). By contrast, neutralization of mitochondrial
matrix PreP protein with PreP antibody revealed an
almost complete inhibition of the degradation of biotin-
labeled A1-40 (Fig. 1D, lanes 4 and 8) as demonstrated
by A immunoreactive bands, whereas no effect on
PreP proteolytic activity for degrading A was seen
in the presence of pF1 antibodies, in which no A
immunoreactive bands were observed (Fig. 1D, lanes 5
and 9). These results verified that hPreP is the protease
responsible for degrading these two different peptides
(A and pF1) in isolated human brain mitochondrial
matrix and that these in vitro degradation assays can be
used to study proteolytic activity in human and mouse
brain mitochondrial matrix.
To determine whether reduced activity of hPreP in
the mitochondrial matrix fraction extracted from tem-
poral lobes of AD patients was due to lower protein
expression of hPreP, we performed Western blot analy-
sis of mitochondrial fractions using specific antibody to
hPreP. Statistical analysis of intensity of immunoreac-
tive hPreP bands normalized to Hsp60 (mitochondrial
protein marker) revealed a slight (11%) but not sig-
nificant decrease in relative expression levels of hPreP
in the temporal lobe of AD individuals compared to
age-matched non-AD subjects (Fig. 1E).
N. Alikhani et al. / Decreased PreP Peptidasome Activity in AD 79
Table 1
The information on the human brain tissues used in the experiments




AD1 M 86 4.4 VI/VI 25–30 per 100×
microscope field
Rare
AD2 F 89 3.3 VI/VI 10–15 per 100×
microscope field
Rare
AD3 F 89 13.6 VI/VI 10–20 per 100×
microscope field
Occasional
AD4 F 81 2.5 VI/VI Up to 30 per 100×
microscope field
Many
AD5 F 89 5.5 VI/VI Up to 30 per 100×
microscope field
Many
AD6 F 89 13.8 VI/VI Up to 10 per 100×
microscope field
Up to 6 per 100×
microscope field
AD7 F 83 NA V/V Severe Up to 20 per 100×
microscope field
AD8 M 75 8.3 III/III Severe Up to 20 per 100×
microscope field
AD9 M 72 2.3 VI/VI Severe Up to 20 per 100×
microscope field
AD10 F 89 3.5 VI/VI Many Up to 20 per 100×
microscope field
AD11 F 89 6.7 VI/VI Up to 25 per 100×
microscope field
Present
AD12 F 89 4.2 VI/VI Up to 30 per 100×
microscope field
Up to 15 per 100×
microscope field
Mean ± SE 9F/3M 85 ± 1.75 6.19 ± 1.24
ND1 M 89 4.9 II/II Very rare Very rare
ND2 M 74 4.3 II/0 Absent Absent
ND3 F 67 5 0 Absent Absent
ND4 M 62 4.3 0 Absent Absent
ND5 M 87 5.2 III/I Absent Absent
ND6 F 76 3.6 0/I Absent Absent
ND7 M 89 3 I/I Absent Absent
NAD8 F 74 18.7 II/0 Absent Absent
Mean ± SE 3F/5M 77.25 ± 3.61 6.13 ± 1.81
AD, Alzheimer’s disease; ND, non-Alzheimer disease; F, female; M, male; PMI, postmortem interval; SE, standard error.
When comparing degradation activity of hPreP in
the cerebella of AD and non-demented individuals,
there was a trend toward lower (but not signifi-
cantly lower) proteolytic activity of hPreP in this part
of AD human brains against biotin-labeled A1-40
(p = 0.185), biotin-labeled A1-42 (p = 0.230), and
pF1 (p = 0.312) (Fig. 2A–C). One likely explana-
tion for these findings might be the fact that there
is a lack of, or at least lower, levels of A accu-
mulation in the cerebellum, less toxicity in the form
of elevated ROS production (Fig. 6B), and therefore
less inhibition of hPreP activity. Proteolytic activity of
hPreP was completely abolished in the presence of oPh
(Fig. 1D lanes 3 and 7, Figs. 2D and 3D, lanes 3). Com-
parison of hPreP expression levels in the cerebellum
mitochondrial matrix of AD and non-AD individuals
revealed no significant change in hPreP protein levels
(Fig. 2E). We also examined whether PreP is able to
degrade the reversed A peptide (A40-1). Incubation
of A40-1 with the recombinant hPreP protein revealed
that the enzyme is able to degrade A40-1 and that the
proteolytic activity is totally inhibited by 20 mM ortho-
phenanthroline (oPh), a metalloprotease inhibitor (data
not shown).
Decreased PreP proteolytic activity in transgenic
AD mice
Since cellular and mitochondrial integrity might
be deteriorated significantly soon after death and the
accompanying tissue disruption might allow poten-
tially non-physiological effects to occur, we studied the
mitochondria isolated from cerebral cortices of trans-
genic AD mice where sample quality was carefully
controlled. Tg mAPP mice overexpressing APP/A
have been well characterized in terms of AD-type
80 N. Alikhani et al. / Decreased PreP Peptidasome Activity in AD
Fig. 1. Changes in hPreP activity/expression in brain mitochondria of AD temporal lobe. Degradation of biotin-A (A, B) and F1 presequence
peptide (C). hPreP proteins extracted from the cortical mitochondria of the indicated AD and non-AD brains (A, B) were incubated with
biotin-labeled A (0.25 g), and then subjected to immunoblotting with Extravidin peroxidase conjugated IgG and detection with ECL to
reveal immunoreactive biotin A. C) For degradation of F1 substrate, mitochondrial hPreP proteins were incubated with pF1 followed by the
immunoblot with antibody to pF1. Densitometry of the combined immunoreactive A (A, B) or F1 bands (C) using NIH Image program is
shown. D) Determination of hPreP proteolytic activity and hPreP-dependent degradation of A in brain mitochondrial fraction. Biotin-labeled A
was completely degraded by the isolated human mitochondrial matrix hPreP protein (MA-hPreP) (lanes 2 and 6). The oPh (ortho-phenantroline,
an inhibitor of PreP proteolytic activity) blocked the degradation of biotin A (lanes 3 and 7). The immuno-inactivation assay confirmed hPreP-
induced degradation of A. When isolated human mitochondrial matrix hPreP protein (MA-hPreP) was pre-incubated with antibody against
hPreP, degradation of A1-40 (lane 4 & 8) was almost completely inhibited, whereas incubation of pF1 presequence antibodies did not affect
A degradation (lanes 5 and 9). E) Immunoblotting of brain mitochondria from AD and non-AD brains for hPreP. The upper panel denotes
representative immunoblots for human PreP and Hsp60. Hsp60 was used as a mitochondrial marker and protein loading controls. The lower
panel shows densitometry of hPreP immunoreactive bands from the indicated brain mitochondria. NS: no statistical significance between these
groups (p > 0.05). Mitochondria were isolated from 12 AD brains and 8 non-AD brains. All experiments were performed in triplicates.
functional, neuropathological, behavioral and electro-
physiological changes [8–10, 12, 26, 37, 38]. Notably,
accumulation of mitochondrial A occurs as early as 4
months of age [8] before the onset of A pathology and
is associated with mitochondrial abnormalities [8–10,
26]. Furthermore, previous studies have shown that
transgenic mice overexpressing mAPP and ABAD
(Tg mAPP/ABAD) manifested excessive production
of reactive free radicals, as well as aberrant mitochon-
drial and neuronal function [8, 10, 26]. Therefore,
we investigated proteolytic activity of PreP in Tg
mAPP/ABAD mice (accelerated AD model) as well
as in Tg mAPP mice and compared the results to Tg
ABAD mice and nonTg littermate controls.
First, proteolytic activity of PreP against all the
three substrates was significantly reduced in the corti-
cal mitochondrial matrix isolated from 5-months-old
Tg mAPP mice compared to nonTg littermate corti-
cal mitochondria: A1-40 (p = 0.02), A1-42 (p = 0.04),
and pF1 (p = 0.04) (Fig. 3A-C). Second, the activity in
Tg mAPP/ABAD mice was significantly lower than
that in both nonTg mice (A1-40, p = 0.007; A1-42,
p = 0.008; and pF1, p = 0.002) and Tg mAPP mice
(p < 0.05). Notably, compared to nonTg cortical mito-
chondria, PreP activity for degrading A (Fig. 3A–B)
was decreased by 2.3- and 3.8-fold in mAPP and
mAPP/ABAD mitochondria, respectively; these data
suggest that increased expression of ABAD in an
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Fig. 2. hPreP activity/expression in the cerebellum of AD and non-AD brains. Mitochondrial hPreP extracted from cerebellum for degrading
biotin A40/42 (A,B) and pF1 (C). Densitometry of A or pF1 immunoreactive bands are shown by diagram bars. D) Effect of hPreP
activity on degrading of F1 presequence (pF1). pF1 was completely degraded by mitochondrial matrix hPreP protein (MA-hPreP, no F1
immunreactive band in lane 2 versus F1 immunoreactive band in lane 1 without MA-hPreP). In the presence of oPh, MA-PreP was not able
to degrade pF1 (lane 3 versus lane 2 without oPh). E) Immunoblotting of cortical mitochondria from AD and non-AD cerebellum for human
PreP. NS: no significant difference. Mitochondria were isolated from 12 AD brains and 8 non-AD brains. All experiments were performed in
triplicates.
A-rich environment significantly diminishes PreP
proteolytic activity. Similarly, PreP activity for degrad-
ing pF1 was also diminished by 3.8- and 7.5-fold in
mAPP and mAPP/ABAD mitochondria in compari-
son to the results from nonTg mitochondria (Fig. 3 C).
The PreP activity against pF1 was inhibited in the
presence of oPh (Fig. 3D). Third, PreP in the brain
cortex mitochondrial matrix isolated from twelve-
month-old Tg mAPP/ABAD mice was less active
in its ability to degrade A1-40 (p = 0.004), A1-42
(p = 0.002), and pF1 (p = 0.003) compared to age-
matched nonTg mice (Fig 4A–C). The ability of PreP
to degrade these three peptides was also significantly
reduced in Tg mAPP mouse brain cortex mitochon-
drial matrix compared to nonTg mice of the same
age (A1-40 (p = 0.004), A1-42 (p = 0.002), and pF1
(p = 0.007)) (Fig. 4A–C). We did not find a signifi-
cant difference of PreP activity between mAPP and
mAPP/ABAD at 12 month old mice as compared
with those of 5 month old mice. ABAD is a co-factor
for exacerbating mitochondrial and neuronal dysfunc-
tion, in particular early stage of Alzheimer’s disease.
Previously, we have demonstrated that neuronal over-
expression of ABAD in mAPP mice had early deficits
in mitochondrial and cognitive dysfunction, which
occurred at 4–5 months old mice [10]. These results are
consistent with our observation that mAPP/ABAD
mice at 5 (not 12) months of age had a significant
decreased PreP activity in brain mitochondria com-
pared to mAPP mitochondria. The results generated
from 12 months old mice could be due to mouse model
used in our study. Because 12 months old mAPP mice
are the end stage of amyloid pathology together with
abnormalities in mitochondrial and neuronal function,
overexpression of ABAD in mAPP mice might not
further exaggerate A-mediated deficits in mitochon-
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Fig. 3. Alterations of PreP activity/expression in transgenic AD mice. Cortical mitochondrial PreP extracted from 5-month-old indicated Tg mice
degraded the biotin A40 (A), A42 (B), and pF1 (C), respectively. Densitometry of A40/42 or pF1 immunoreactive bands was performed
using NIH image program. The upper panels indicate the representative immunoblots for A (A, B) and pF1 (D). In the presence of oPh,
mitochondrial PreP was not able to degrade pF1 peptide (lane 3 vs. lane 2). E) Immunoblotting of cortical mitochondrial protein from the
indicated Tg mice for PreP. Representative immunoblots for PreP and Hsp60 are shown in the upper panel. Hsp60 (mitochondrial marker) was
used as protein loading control and mitochondrial rich fractions. n = 4–7 mice per group. All experiments were performed in triplicates.
drial and neuronal properties. To determine whether
decreased PreP activity was due to alteration in PreP
expression, mitochondrial proteins extracted from Tg
mice were subjected to the immunoblotting with the
specific antibody to PreP. Similar levels of PreP pro-
tein were expressed in all groups of Tg mice (Fig. 3E
and 4D, p > 0.05). To determine whether the alterations
in PreP activity occurred before accumulation of mito-
chondrial A, we measured PreP activity in 2 months
old cortical mitochondria. There were no significant
differences of PreP activity between mAPP cortical
mitochondria and nonTg cortical mitochondria at the
age of 2 month prior to detectable mitochondrial A
accumulation (data not shown).
When comparing the activity of PreP in five-months
and twelve-months-old nonTg, and Tg mAPP mice,
we found that proteolytic activity decreased in an age-
dependent manner (Fig. 5A–C). There was a significant
difference in the capacity of PreP to degrade pF1
in five-months-old nonTg and Tg mAPP mice com-
pared to twelve-months old mice (Fig. 5 C). A probable
explanation for these observations may be the effect of
aging. Interestingly, when comparing the proteolytic
activity of PreP in five-months and twelve-months-old
Tg mAPP mice, a significant difference was noted
in degradation against all three peptides, possibly due
to overproduction of mAPP and consequently ele-
vated A generation and accumulation that enhances
the effect of aging thereby affecting PreP activity.
Mitochondrial oxidative stress and mitochondrial
dysfunction in Aβ-rich mitochondria
In light of elevated levels of oxidative stress in the
AD brain and A-rich mitochondria, and the potential
effects of oxidative stress on PreP activity, we mea-
sured HNE levels, an oxidative stress marker, in the
mitochondrial fractions used in the present studies. As
shown in Fig. 6, HNE levels were significantly ele-
vated in the AD temporal lobe mitochondria compared
with non-AD mitochondria (Fig. 6A), while levels of
HNE in cerebellum mitochondria were comparable
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Fig. 4. PreP activity/expression in Tg AD mice at age of twelve months. The cortical mitochondrial PreP from twelve-months-old Tg mice
degraded biotin A40/42 (A,B) and pF1 (C) Densitometry of combined immunoreactive bands (A or pF1) from the indicated Tg mice.
D) Immunoblotting of mitochondrial fractions from the indicated Tg mice for PreP or Hsp60. n = 4–5 mice per group. All experiments were
performed in triplicates.
Fig. 5. Age-dependent decreased PreP activity in Tg mAPP mice. Cortical mitochondrial PreP was extracted from Tg mAPP and nonTg mice
at ages of five and twelve months, and then incubated with biotin A40/42 (A, B) and pF1 (C), respectively. Densitomery of all immunoreactive
bands for A and pF1 is shown. n = 4–6 mice per group. All experiments were performed in triplicates.
between AD and non-AD (Fig. 6B). Similarly, HNE
levels were significantly higher in mAPP mitochon-
dria than in nonTg mitochondria. The mAPP/ABAD
mitochondria exhibited increased HNE levels com-
pared to mAPP mitochondria (Fig. 6C) as early as
five months old. These results are consistent with our
previous observation that overexpressed ABAD in Tg
mAPP mice enhanced generation of reactive free rad-
icals [10].
Next, we measured the activity of cytochrome c
oxidase, a key respiratory enzyme, in human brain
mitochondria to determine the correlation of mitochon-
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Fig. 6. A. HNE levels and cytochrome c oxidase activity in brain mitochondria. HNE levels in cortical mitochondria isolated from temporal lobe
(A) and cerebellum (B) of AD and non-AD brains were measured by ELISA. n = 10–11 mice per group. C) HNE levels in cortical mitochondria
from the indicated Tg mice were determined by ELISA. *p < 0.05 vs. nonTg mice, #p < 0.05 vs. nonTg and mAPP mice. n = 8–9 mice per
group. D) Cytochrome c oxidase activity in cortical mitochondria from temporal lobe and cerebellum of AD and non-AD subjects. E) Decreased
hPreP activity in mitochondrial matrix in the presence of 0.1 mM and 1 mM K3Fe(CN)6 (lanes 3 and 4).
drial function to the alterations in PreP. Cytochrome c
oxidase activity was significantly decreased in cortical
mitochondria from AD temporal lobe ( 50–60% lower
than non-AD mitochondria); but only a small change in
cytochrome c oxidase activity (10% change) was noted
in cerebellum mitochondria when comparing AD and
non-AD brains (Fig. 6D). These studies suggest that
aberrant mitochondrial function from A-rich mito-
chondria of AD-affected brain correlates to alterations
in PreP proteolytic activity.
We have also investigated PreP activity against
A1-40 in the mitochondrial matrix under oxidized
conditions, in the presence of increasing concentra-
tions of K3Fe(CN)6. PreP activity was completely
inhibited at 1 mM K3Fe(CN)6 (Fig. 6E). This is in
agreement with our previous results [27], in which
we have shown that degradation of A1-40 with
recombinant hPreP was totally reduced under oxidized
conditions.
DISCUSSION
Several lines of evidence suggest that steady-state
levels of A, a fundamental feature of AD, are achieved
by a balance between A generation and clearance
and that disruption of the clearance system gives rise
to increased A accumulation. Several proteases have
recently been shown to be involved in regulation of the
steady-state level of A including IDE, a cytoplasmic
functional analogue of hPreP, and neprilysine (NEP), a
plasma membrane-anchored zinc metallprotease. Both
have been extensively studied and are implicated in
AD [39–41]. Several reports emphasize the potentially
important role of mitochondrial dysfunction and ele-
vated ROS production in AD development [10, 12,
26, 42–44]. A accumulation in this vital organelle
has been reported to occur in brain mitochondria of
AD transgenic mice models prior to the extracellular
A deposits and to cause increases in ROS production
[10, 26]. Elevated levels of oxidative stress have also
been observed in A-affected areas in postmortem AD
brains [8]. We have identified PreP as the novel A-
degrading protease in human brain mitochondria [27].
In the present studies, we show that hPreP prote-
olytic activity is reduced in the AD-affected region,
temporal lobe, while similar results were not observed
in the AD-spared cerebellum, a region often free of
A accumulation. Proteolytic activity of hPreP in
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mitochondrial matrix isolated from temporal lobe of
AD patients and non-AD age-matched controls was
measured with three different peptides (biotin labeled
A1-40, biotin labeled A1-42, and pF1) using an
in vitro degradation assay; further, hPreP activity in
isolated cerebellum mitochondrial matrix of AD indi-
viduals was compared to age-matched controls. A
significant reduction in PreP function was also con-
firmed in AD transgenic mice models (Tg mAPP
and Tg mAPP/ABAD) compared to nonTg mice
using the above listed peptides as substrates. Biotin
labeled A in the degradation assays was used to
distinguish it from the A accumulated in AD brain
mitochondria and transgenic mice models. pF1, a 53
amino acid long mitochondrial presequence peptide,
was used as a non-A substrate to further deter-
mine PreP proteolytic activity. Although these peptides
have slightly different properties (as A peptides
are negatively charged, whereas pF1 is positively
charged), hPreP degraded these substrates with similar
efficiency. Importantly, A-containing mitochondria
from AD, mAPP, or mAPP/ABAD brains showed
significantly decreased PreP proteolytic activity for
degrading both A and non-A substrates. Accord-
ingly, mitochondrial respiratory function was also
reduced in these AD mitochondria as well as in mAPP
or mAPP/ABAD mitochondria [8, 9, 12, 13, 26].
The strong negative correlation between PreP activ-
ity and mitochondrial A accumulation suggests that
functional PreP is important for maintenance of mito-
chondrial function through its capabilities to detoxify
and to clear mitochondrial A.
hPreP is a metalloprotease that is able to degrade
mitochondrial presequences after they have been
cleaved off from precursor proteins as well as other
unstructured peptides in the range of 10 to 70
amino acid residues. We have previously reported that
recombinant hPreP degraded both the mitochondrial
presequence pF1 as well as A1-40, A1-42, and A
Arctic (E22G) peptides [26]. Here, we demonstrate
that hPreP is also able to degrade A40-1. This find-
ing is not surprising as PreP is a general peptidasome
with a preference for positively charged amino acids in
the P1´ position and small-uncharged residues or ser-
ine residues in the P1 position and it does not exhibit
any unique cleavage specificity [33]. Most importantly,
under physiological and pathological conditions such
as AD, reversed A40-1 peptide is not present in both
human and mouse brains, which is not relevant to
human disease.
Since no change was observed in the protein expres-
sion level of hPreP in AD cases versus non-AD
individuals or in the AD transgenic mice models ver-
sus nonTg mice, the reduced proteolytic ability of PreP
is most probably due to AD-related PreP functional
alteration. When comparing the gene expression levels
in the brain of APP overexpressing mice of differ-
ent ages to age-matched nonTg mice, Reddy et al.
[45] observed a consistent increase of mRNA corre-
sponding to proteins involved in mitochondrial energy
metabolism and apoptosis, but they did not report any
change in the mRNA levels of PreP, which is in agree-
ment with our protein expression data. hPreP contains
two cysteines situated close to each other. Under oxi-
dized conditions these cysteines form a disulphide
bridge locking the two protein halves of the enzyme
in a closed conformation generating an inactive PreP
[27]. These cysteines are conserved in all mammalian
homologues of PreP. Measurement of the proteolytic
activity of hPreP in the presence of an oxidizing K3Fe
(CN)6 shows complete inhibition. Reduction of hPreP
proteolytic activity observed in AD-affected areas of
brain may thus be due to formation of the disulphide
bridge that occurs because of the elevated ROS for-
mation (that occurs in the vulnerable regions of AD
brain). However, attempts to reactivate the enzyme by
pre-incubating isolated matrix fraction with DTT, a
reducing agent, revealed inconsistent results indicat-
ing that other factors, such as amino acid modification
rather than disulphide bond formation may be respon-
sible for inactivation of the enzyme.
Notably, PreP activity was significantly diminished
in the A-enriched mitochondria as compared with
the nonTg mitochondria, suggesting the association
of mitochondrial A with alterations in PreP activ-
ity. Indeed, our recent study indicates that increased
PreP activity in Tg mAPP mice significantly reduced
mitochondrial A accumulation [51] Furthermore,
our data also revealed an age-related reduction of
PreP function in transgenic mice models, which sug-
gests that the PreP activity may decrease during
aging.
In summary, our data clearly demonstrate that PreP
proteolytic activity was significantly reduced in A-
enriched mitochondria such as in AD-affected brains
and AD mouse models. Levels of PreP activity nega-
tively correlate to mitochondrial oxidative stress and
positively associate with mitochondrial respiratory
function. Deficits in PreP proteolytic activity observed
in AD brain may be a significant contributing fac-
tor leading to cerebral A accumulation, which in
turn results in mitochondrial dysfunction. For future
areas of investigation, it will be important to elucidate
the mechanisms underlying reduced PreP function in
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AD-affected regions of the brain. The current data
provides important evidence for AD- and age-related
alterations of this mitochondrial A-degrading pro-
tease, and may open avenues to new pharmacological
approaches or gene therapy to upregulate PreP activity
or increase PreP levels that will enhance A clearance
in mitochondria and thereby halt disease progression.
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